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 Abstract 
  Thrombin and plasmin are serine proteases involved in blood coagulation and fibrinolysis, 
whose precursors are circulating in blood stream.  These blood-derived proteases may play 
important roles in the pathogenesis of intracerebral hemorrhage by acting on brain 
parenchymal cells.  We previously reported that thrombin induced delayed neuronal injury 
through extracellular signal regulated kinase (ERK)-dependent pathways.  Here we 
investigated potential cytotoxic actions of plasminogen, a precursor protein of plasmin, using 
slice cultures prepared from neonatal rat brain and intracortical microinjection model in adult 
rats.  Although plasminogen alone did not evoke prominent neuronal injury, plasminogen 
caused significant neuronal injury when combined with a moderate concentration of thrombin 
(30 U/ml) in the cerebral cortex of slice cultures.  The cortical injury was prevented by 
tranexamic acid and aprotinin.  The combined neurotoxicity of thrombin and plasminogen 
was also prevented by PD98059, an inhibitor of ERK pathway, as well as by other agents that 
have been shown to prevent cortical injury induced by a higher concentration (100 U/ml) of 
thrombin alone.  ERK phosphorylation after plasminogen exposure was localized in cortical 
astrocytes.  Moreover, microinjection of plasminogen in vivo potentiated thrombin-induced 
cortical injury, and inhibition of plasmin ameliorated hemorrhage-induced neuronal loss in the 
cerebral cortex.  These results suggest that plasminogen/plasmin system augmenting 
thrombin neurotoxicity participates in hemorrhagic cortical injury. 
 
Keywords: collagenase; cortical cells; hemorrhagic brain injury; plasminogen; slice cultures; 
thrombin 
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Introduction 
  Intracerebral hemorrhage (ICH) represents an acute stroke characterized by extravasation 
of blood into brain parenchyma and formation of hematoma.  While ICH accounts for 15% 
of all strokes, no satisfactory medical treatments have been developed against this disorder, 
and patients suffer from poor prognosis and high mortality.  After hemorrhagic ictus, 
hematoma may cause brain injury via cytotoxicity of blood-derived molecules as well as via 
mass effects (Xi et al., 2006).  Thrombin is one of the major blood-derived serine proteases 
released into brain parenchyma when cerebral vessels are ruptured.  Besides its important 
role in blood coagulation, thrombin can induce neuronal apoptotic death and microglial 
activation in various experimental models (Donovan et al., 1997; Fujimoto et al., 2006, 
2007). 
  Plasmin is another serine protease derived from a circulating precursor protein, 
plasminogen.  Cleavage between Arg-560 and Val-561 of plasminogen molecule, which is 
catalyzed by plasminogen activators such as urokinase and tissue-type plasminogen activators, 
generates plasmin (Robbins et al., 1967).  Plasmin is well known as a fibrinolytic serine 
protease that interacts with polymerized fibrin clots to release free fibrin molecule and 
dissolve clots (Castellino and Ploplis, 2005).  The catalytic domain of plasmin is localized in 
the light chain derived from the carboxyl-terminus of plasminogen, whereas five kringle 
domains are within the heavy chain from the amino-terminus of plasminogen (Patthy, 1985).  
The kringle domain of plasmin(ogen) possesses lysine-binding activity, and plasminogen 
binds its substrates such as fibrin through lysine-binding sites, which results in the 
enhancement of plasmin generation (Hajjar et al., 1986; Wu et al., 1990). 
  Plasmin(ogen) may have physiological/pathophysiological functions in the central nervous 
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system, since expression of plasminogen has been detected in central neurons (Tsirka et al., 
1997a).  In a pathological context, neuroxicity of plasminogen in the striatum has been 
demonstrated in an in vivo experimental model (Xue and Del Bigio, 2001, 2005).  In 
addition, plasmin-mediated degradation of the extracellular matrix enhances vulnerability of 
hippocampal neurons to excitotoxins (Chen and Strickland, 1997; Tsirka et al., 1997b).  A 
detrimental role of plasminogen/plasmin system in ischemic brain injury has also been 
proposed (Takahashi et al., 1997). 
  When ICH occurs, circulating plasminogen and plasminogen activators are released into 
the cerebral parenchyma, and plasmin generated at the hemorrhagic sites may contribute to 
the brain injury after ICH.  In the present study, we investigated pathogenic roles of 
plasminogen with relation to ICH.  We particularly focused on the interaction of 
plasminogen with the neurotoxic actions of thrombin. 
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Materials and Methods 
Drugs and chemicals 
  Drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise 
indicated.  Thrombin from bovine plasma (catalog No. T4648), bovine serum albumin 
(catalog No. A2153), aprotinin from bovine lung and clodronate were obtained from Sigma 
(St. Louis, MO, USA).  Tranexamic acid was from Aldrich (St. Louis, MO, USA).  
Plasminogen from human plasma (catalog No. 528175), plasmin from human plasma (catalog 
No. 527621), PD98059, SB203580, 
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and 
bisindolylmaleimide (BIM) were from Calbiochem (San Diego, CA, USA).  SP600125 was 
from Tocris Cookson (Bristol, UK).  Argatroban was from Sawai Pharmaceutical (Osaka, 
Japan).  Cycloheximide was from Wako Pure Chemical (Osaka, Japan). 
 
Preparation of slice cultures 
  All experimental procedures were approved by our institutional animal experimentation 
committee, and animals were treated in accordance with the guidelines of the NIH regarding 
the care and use of animals for experimental procedures.  Organotypic slice cultures were 
prepared essentially according to the methods described previously (Fujimoto et al., 2006).  
Coronal brain slices of 300 μm thickness were prepared from Wistar rats at postnatal days 3 - 
4 (Nihon SLC, Shizuoka, Japan), and six cortico-striatal tissue slices were transferred onto a 
30-mm Millicell-CM insert membrane (Millipore, Bedford, MA, USA) in six-well plates.  
Culture medium, consisting of 50% minimum essential medium/HEPES (GIBCO, Invitrogen 
Japan, Tokyo, Japan), 25% Hanks’ balanced salt solution (GIBCO) and 25% heat-inactivated 
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horse serum (GIBCO) supplemented with 6.5 mg/ml D-glucose and 2 mM L-glutamine, 100 
U/ml penicillin G potassium and 100 μg/ml streptomycin sulfate (GIBCO), was supplied at 
0.75 ml/well so that the slices were maintained at liquid/air interface.  Culture medium was 
replaced with fresh one on the next day of culture preparation, and thereafter, every two days.  
Slices were cultured in a humidified atmosphere of 5% CO2 and 95% air at 34°C. 
 
Drug treatment and cell death assessment 
  Cultured slices at 9 - 11 days in vitro were incubated for 24 - 48 h in serum-free medium, 
where minimum essential medium/HEPES substituted for horse serum.  Then slices were 
exposed to drugs and chemicals dissolved in serum-free medium for indicated periods.  To 
assess cell injury, propidium iodide (PI; 5 μg/ml, Wako Pure Chemical) was added to 
serum-free medium for drug treatment.  After 72 h, images of PI fluorescence of each slice 
were captured through a monochrome chilled CCD camera (C5985; Hamamatsu Photonics, 
Hamamatsu, Japan) and stored as image files.  The average signal intensity in an area of 180 
μm × 180 μm within the parietal cortex was obtained as the fluorescence value of each slice, 
with the use of NIH Image 1.63 software.  In each experiment, slice cultures treated with 
100 μM N-methyl-D-aspartate (NMDA) for 72 h were used to determine the degree of the 
standard injury.  Fluorescence values were normalized with the intensity of cultures that 
received standard injury as 100%.  Images of whole slice cultures were also obtained, and 
the area of the striatal region in each slice was estimated with NIH Image 1.63. 
 
Immunohistochemistry for slice cultures 
After drug treatment, slice cultures were fixed with 0.1 M phosphate buffer containing 4% 
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paraformaldehyde and 4% sucrose for 2 h.  After rinsing with phosphate-buffered saline 
(PBS), they were permeabilized and blocked with 0.2% Triton X-100 in PBS containing 
1.5 % goat serum followed by incubation with primary antibodies overnight at 4°C.  Primary 
antibodies were mouse anti-NeuN (1:200, Chemicon International, Temecula, CA, USA), 
mouse anti-OX42 (1:300, Dainippon Pharmaceutical, Osaka, Japan), mouse anti-glial 
fibrillary acidic protein (GFAP) (1:500, Sigma) and rabbit anti-phospho-p44/42 MAP kinase 
(T202/Y204) (1:250, Cell Signaling Technology, Beverly, MA, USA).  After rinse with PBS, 
cultures were incubated with secondary antibodies for 1 h at room temperature.  Alexa Fluor 
488-labeled goat anti-mouse IgG (1:200, Molecular Probes, Eugene, OR, USA), Alexa Fluor 
594-labeled goat anti-mouse IgG (1:200, Molecular Probes) and Alexa Fluor 488-labeled goat 
anti-rabbit IgG (1:200, Molecular Probes) were used as secondary antibodies.  Then cultures 
were rinsed with PBS and specimens were dehydrated through a graded ethanol series and 
mounted on slide glasses with glycerol.  Fluorescence signals were observed with a 
laser-scanning confocal microscopic system (MRC1024, Biorad, Hercules, CA, USA). 
 
Plasmin activity quantification 
 Protease activity of plasmin was measured by the rate of substrate cleavage according to a 
previous report (Schneider and Nesheim, 2004) with modification.  D-Val-Leu-Lys 
p-nitroanilide (S2251 reagent, Sigma), a chromogenic substrate of plasmin, was dissolved in 
50 mM Tris-buffered saline at a concentration of 2 mM.  Serum-free media with or without 
drugs and culture supernatants were reacted with an equal amount of S2251 solution at room 
temperature.  Absorobance of p-nitroaniline generated by the cleavage of S2251 reagent was 
measured at 450 nm on a microplate reader from 3 min to 180 min after initiation of the 
7 
reaction. 
 
Western blot analysis 
  After treatment with drugs for indicated periods, slice cultures were harvested and 
homogenized in ice-cold lysis buffer containing 20 mM Tris-HCl (pH 7.0), 25 mM 
β–glycerophosphate (Sigma), 2 mM EGTA·2Na, 1% Triton X-100, 1 mM vanadate, 1% 
aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride and 2 mM dithiothreitol.  Samples 
were mixed with sample buffer composed of 124 mM Tris-HCl (pH 6.8), 4% sodium dodecyl 
sulfate (SDS), 10% glycerol, 0.02% bromophenol blue and 4% 2-mercaptoethanol.  After 
boiling for 5 min, samples were subjected to 12% SDS-polyacrylamide gel electrophoresis for 
70 min, followed by transfer to PVDF membrane (Millipore) for 70 min.  Membranes were 
blocked with 5% nonfat milk and subsequently probed overnight with mouse 
anti-phospho-p44/42 MAP kinase (T202/Y204) (1:2000, Cell Signaling Technology) and 
anti-p44/42 MAP kinase (1:1000, Cell Signaling Technology).  The membranes were rinsed 
and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:10000, Jackson 
Immunoreseach Laboratories, West Grove, PA, USA) or goat anti-rabbit IgG (1:10000, 
Jackson Immunoreseach Laboratories).  Following incubation with secondary antibodies, 
membranes were rinsed and bound antibodies were detected with enhanced 
chemiluminescence kit (Amersham Biosciences, Buckinghamshire, UK) according to the 
manufacturer’s instructions.  The band intensities were analyzed with NIH image 1.63. 
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Surgical procedures for microinjection and drug administration 
  Male Sprague-Dawley rats initially weighing 220 - 280 g were used.  Animals were kept 
at constant ambient temperature (23 ± 2 °C) under a 12-h light and dark cycle with free access 
to food and water.  Drug administration was performed according to a previous report 
(Fujimoto et al., 2007) with modification.  Briefly, rats were anesthetized with pentobarbital 
(50 mg/kg, i.p., Dainippon Sumitomo Pharmaceutical, Osaka, Japan) and placed in a 
stereotaxic frame (Narishige, Tokyo, Japan).  After scalp incision, a hole was drilled on the 
skull.  Thrombin, plasminogen and collagenase were administered via a stainless steel 
injection cannula (o.d. 0.35 mm) into the parietal cortex at 0.2 mm anterior, 3.0 mm lateral, 
2.5 mm ventral from bregma.  The solution of these drugs in a volume of 2 μl/rat was 
infused at a constant rate of 0.5 μl/min.  The injection cannula was left in place at least for 
additional 5 min to prevent backflow of drugs.  Aprotinin and tranexamic acid were given 
intraperitoneally.  Aprotinin was administered at a dose of 2 mg/kg at 30 min after 
intracortical injection of collagenase, followed by administration of 1 mg/kg from the next 
day twice daily.  Tranexamic acid was administered at a dose of 300 mg/kg at 30 min after 
intracortical injection of collagenase, followed by administration of 150 mg/kg from the next 
day twice daily.  Control rats received intraperitoneal injection of the equivalent volume of 
saline. 
 
Histological examinations after microinjection 
  After indicated periods from intracortical injection, rats were anesthetized again and 
perfused through the heart with PBS followed by 4% paraformaldehyde.  Brains were 
removed from the skull, and postfixed in 4% paraformaldehyde and dehydrated with 15% 
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sucrose solution for overnight at 4°C.  After freezing, coronal brain sections (16 μm) 
containing the injection site were prepared and mounted onto slides.  For 
immunohistochemitry, specimens were autoclaved (121°C for 15 min) for epitope retrieval.  
They were permeabilized and blocked with 0.5% Triton X-100 in PBS containing 1.5% horse 
serum for 1 h at room temperature.  Specimens were then incubated with mouse anti-NeuN 
(1:200) overnight at 4°C, and after rinse with PBS, they were incubated with biotinylated 
horse anti-mouse IgG (1:200, Vector Laboratories, Burlingame, CA, USA) for 1 h at room 
temperature.  After rinse, specimens were treated with avidin-biotinylated horseradish 
peroxidase complex (Vectastain Elite ABC kit, Vector Laboratories), and then peroxidase was 
visualized with diaminobenzidine and H2O2.  Bright-field images were captured through a 
monochrome chilled CCD camera.  For injury induced by thrombin with or without 
plasminogen, we defined the region where no NeuN-positive cells were observed as the 
injured region, and measured the injured area with NIH Image 1.63.  For injury resulting 
from collagenase-induced hemorrhage, we counted the number of NeuN-positive cells in an 
area of 230 μm × 320 μm at the center of hematoma formed in the cortex. 
 
Statistics 
  Data are expressed as means ± SEM.  Statistical significance of difference was evaluated 
with paired t-test, Mann-Whitney U-test or one-way analysis of variance followed by 
Student–Newman–Keuls' test.  Probability values less than 5% were considered significant.
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Results 
  We applied plasminogen (0.1 – 10 U/ml) for 72 h to cortico-striatal slice cultures.  PI 
fluorescence was used as a measure of cell injury in the cortical region.  Plasminogen up to 
10 U/ml did not induce cortical cell injury (Fig. 1F).  Moreover, while we have previously 
shown that thrombin induced shrinkage of the striatal tissue in slice culture (Fujimoto et al., 
2006), we did not observe any changes in the striatal area after application of plasminogen 
(data not shown).  Notably, when plasminogen at 3 U/ml, but not at 1 U/ml, was applied to 
slice cultures concomitantly with a moderate concentration (30 U/ml) of thrombin that did not 
induce prominent cortical injury by itself, a significant degree of cortical injury was evident at 
72 h (Fig. 1A-D, G).  When plasminogen was applied from 24 h before application of 30 
U/ml thrombin, significant cortical injury was produced also at 1 U/ml and in a 
concentration-dependent manner bewteen 1 – 3 U/ml (data not shown).  PI fluorescence in 
the cortical region of slice cultures treated with a combination of thrombin and plasminogen 
was colocalized with immunoreactivity against NeuN, a neuronal marker (Fig. 1E), 
suggesting that neurons were injured by this treatment.  On the other hand, plasminogen did 
not potentiate NMDA-induced cortical neuron injury, even when slices received 24-h 
pretreatment with plasminogen (Fig. 1H).  In addition, plasminogen did not affect the degree 
of striatal shrinkage induced by thrombin (Fig. 1I).  Plasminogen did not show any toxic 
effects when combined with bovine serum albumin at a protein concentration corresponding 
to that of 30 U/ml thrombin (data not shown).  These results suggest that plasminogen 
specifically evokes cortical injury by a combination with thrombin. 
  Plasminogen can be converted into a serine protease plasmin by plasminogen activators.  
We then examined the involvement of plasmin protease activity on cortical injury induced by 
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thrombin and plasminogen.  To measure plasmin activity, we incubated serum-free medium 
containing plasmin (0.1 U/ml) or plasminogen (3 U/ml) with a chromogenic substrate, S2251, 
at room temperature.  Analysis of the absorbance of the degradation product indicated that 
plasmin cleaved S2251 time-dependently, whereas medium alone or plasminogen was without 
effect (Fig. 2A), confirming that S2251 was a suitable substrate of plasmin but not of 
plasminogen.  Based on these observations, we examined whether plasmin was generated 
after application of plasminogen to slice cultures.  The supernatants of slice cultures treated 
with 3 U/ml plasminogen for 72 h cleaved S2251 gradually, whereas those of slice cultures 
treated with vehicle showed no effect (Fig. 2B).  These results suggest that a fraction of 
plasminogen was converted into plasmin during incubation with slice cultures.  Moreover, 
cortical injury induced by thrombin plus plasminogen was prevented by aprotinin (20 μg/ml), 
a plasmin inhibitor, and tranexamic acid (3 mM), a lysine analog that inhibits plasminogen 
activation (Fig. 2C, D).  In this set of experiments, we used aprotinin and tranexamic acid at 
concentrations that were sufficient to inhibit plasmin activity but did not inhibit thrombin 
activity (Engles, 2005).  Indeed, aprotinin and tranexamic acid did not ameliorate cortical 
injury induced by a high concentration (100 U/ml) of thrombin (Fig. 2E, F), suggesting that 
the effects of these drugs were mediated by inhibition of plasmin activity. 
  We previously demonstrated that thrombin-induced cortical injury was prevented by 
inhibition of extracellular signal-regulated kinase (ERK) pathway, Src family tyrosine kinase, 
protein kinase C (PKC) and de novo protein synthesis as well as by an inhibitor of thrombin 
protease activity.  In contrast, inhibition of p38 mitogen-activated protein kinase (MAPK) 
and depletion of microglia had no effect, and inhibition of c-Jun N-terminal kinase (JNK) 
exacerbated thrombin-induced cortical injury (Fujimoto et al., 2006).  Then, we examined 
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the involvement of these pathways in neurotoxicity of thrombin plus plasminogen.  Selective 
inhibitors for various signaling pathways were used at the same concentrations as those used 
in our previous study (Fujimoto et al., 2006).  As shown in Fig. 3A-E, the combined 
neurotoxicity of thrombin and plasminogen in the cortical region was prevented by inhibitors 
of ERK pathway (PD98059, 100 μM), Src family tyrosine kinase (PP2, 100 μM), PKC (BIM, 
3 μM), de novo protein synthesis (cycloheximide, 1 μg/ml) and thrombin protease activity 
(argatroban, 300 μM).  On the other hand, an inhibitor of p38 MAPK (SB203580, 100 μM) 
and depletion of microglia by clodronate (100 μg/ml) did not prevent cortical injury, and an 
inhibitor of JNK (SP600125, 100 μM) exacerbated the injury (Fig. 3F-H).  Overall, the 
effects of various agents on neurotoxicity of thrombin plus plasminogen were similar to those 
on neurotoxicity of a high concentration of thrombin alone (Fujimoto, et al., 2006). 
  We further investigated the involvement of ERK in combined neurotoxicity of thrombin 
and plasminogen.  Levels of ERK phosphorylation in slice cultures were examined by 
Western blot analysis after 3 h or 24 h of incubation with or without thrombin and 
plasminogen.  At 3 h, plasminogen (3 U/ml) increased phosphorylated ERK level to 267 ± 
55% of vehicle treatment (n=8, P=0.019, evaluated by paired t-test).  The elevated level of 
ERK phosphorylation was sustained even after 24 h from the onset of plasminogen treatment 
(Fig. 4A).  Consistent with our previous study (Fujimoto et al., 2006), thrombin also caused 
ERK phosphorylation at 3 h, which declined thereafter (Fig. 4A).  To determine cell types 
exhibiting ERK phosphorylation after 3 h of plasminogen treatment, we performed 
immunofluorescence staining with a combination of antibodies against phosphorylated ERK 
and cell type-specific marker proteins.  The majority of phosphorylated ERK 
immunofluorescence in the cortical region was colocalized with immunofluorescence of an 
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astrocyte marker, GFAP (Fig. 4B), but not with a neuronal marker, NeuN (Fig. 4C) or a 
microglial marker, OX42 (data not shown).  These results suggest that plasminogen evokes 
persistent ERK phosphorylation in cortical astrocytes. 
  On the basis of these in vitro observations, we next examined whether plasminogen could 
potentiate thrombin neurotoxicity in vivo.  For this purpose, we injected thrombin with or 
without plasminogen into the rat cortex.  The dose of thrombin was set to 1 U, because in 
preliminary experiments 10 U thrombin alone caused severe cortical injury.  After 72 h, 
several coronal brain sections were prepared from each rat and immunostained with 
anti-NeuN antibodies.  As shown in Fig. 5A, thrombin injection into the cerebral cortex 
produced a distinct region with decreased NeuN immunoreactivity around the injection site, 
as with the case of thrombin injection into the striatum in our previous study (Fujimoto et al., 
2007).  Since there were very few NeuN-positive cells within this region and we could easily 
distinguish the border between the injured region and the intact region, we assessed the 
degree of neurotoxicity by the injured area defined as the region with scarce 
NeuN-immunoreactivity around the injection site.  As expected, the injured area of the 
section containing the injection site, as revealed by a cannula track, was the largest among 
several coronal brain sections examined.  This means that the cortical injury expanded 
concentrically from the injection site.  In this series of experiments, plasminogen (0.3 U) 
again augmented thrombin-induced cortical injury at 72 h (Fig. 5B and C). 
  Finally, we examined possible involvement of plasminogen in hemorrhage-induced brain 
injury in vivo.  Injection of 0.1 U collagenase into the rat cortex led to hematoma formation 
and a substantial decrease of NeuN-positive cells inside the hematoma.  Unlike in the case of 
thrombin injection, however, a moderate number of NeuN-positive cells remained viable even 
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in the center of the collagenase injection site (Fig. 6A, B, E, F).  Therefore, we evaluated 
neuroprotective effects of drugs by the number of NeuN-positive cells at the hematoma center 
72 h after collagenase injection.  Aprotinin (2 mg/kg/day) intraperitoneally administered 
after collagenase injection partially but significantly increased the number of NeuN-positive 
cells at the hematoma center, compared with saline-administered control (Fig. 6C, G, I).  
Tranexamic acid (300 mg/kg/day) also tended to increase the number of surviving 
NeuN-positive cells, although the effect did not reach statistical significance (Fig. 6D, H, I).  
The dose of aprotinin in this set of experiments was almost maximal one that could be 
prepared from the commercial product (Sigma, A6279), and the dose of tranexamic acid was 
chosen according to a previous report (O’Brien et al., 2000).  We also compared the 
hematoma size of each treatment group.  When the area of hematoma was defined as the 
cortical region with decreased NeuN-immunoreactivity in the coronal brain section containing 
the injection site, hematoma size of saline-administered control was 2.12 ± 0.28 mm2 (n=10).  
Hematoma sizes of rats treated with aprotinin and tranexamic acid were 2.63 ± 0.30 mm2 
(n=9) and 2.70 ± 0.41 mm2 (n=7), respectively, both of which were not significantly different 
from that of control group.  These results suggest that neuroprotective effect afforded by 
regulation of plasmin activity is independent of inhibition of fibrinolytic activity of plasmin. 
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Discussion 
  Plasminogen is a circulating zymogen of fibrinolytic serine protease plasmin, and plasma 
concentration of plasminogen is estimated to be ~2 U/ml (Xue and Del Bigio, 2005).  
Although neurotoxicity of plasminogen in the striatum has been reported by in vivo 
experimental model (Xue and Del Bigio, 2001, 2005), we did not observe neurotoxicity of 
plasminogen in cortico-striatal slice cultures even at 10 U/ml, a higher concentration than that 
in plasma.  Instead, we found that a prominent effect of plasminogen was potentiation of 
neurotoxicity of thrombin (30 U/ml) in the cerebral cortex.  As previously demonstrated, 
thrombin alone can produce cortical injury at a higher concentration of 100 U/ml (Fujimoto et 
al., 2006).  Therefore, the action of plasminogen can be viewed as lowering of the threshold 
of neurotoxic actions of thrombin.  The plasma concentration of prothrombin, the precursor 
of thrombin, is estimated to be 200 U/ml (Lee et al., 1996), which means that the 
concentration of thrombin used in the present study (30 U/ml) is probably attainable in the 
case of hemorrhagic events.  Plasminogen had no effect on thrombin toxicity in the striatum, 
which may reflect the fact that the cellular mechanisms of thrombin neurotoxicity are 
different between the cerebral cortex and the striatum (Fujimoto et al., 2006). 
  We also suggest that the potentiating effect of plasminogen on thrombin neurotoxicity was 
mediated by plasmin generated from plasminogen processing.  This view was supported by 
the finding that the supernatant of slice cultures treated with plasminogen exhibited plasmin 
activity.  Moreover, cortical injury induced by a combination of thrombin and plasminogen 
was abolished by aprotinin, a plasmin inhibitor.  Although aprotinin is a protease inhibitor 
with a broad spectrum, the concentration of aprotinin applied to slice cultures (20 μg/ml), 
corresponding to ~0.6 μM, was much lower than the concentration that inhibited thrombin (30 
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μM; Engles, 2005).  Moreover, aprotinin did not abolish cortical injury and striatal shrinkage 
induced by a higher concentration of thrombin.  Therefore, the effect of aprotinin on 
neurotoxicity of thrombin plus plasminogen was likely attributable to inhibition of plasmin 
activity. 
  Similar to aprotinin, tranexamic acid abolished cortical injury induced by combined 
application of thrombin and plasminogen, without any effect on injury induced by a high 
concentration of thrombin.  These results indicate that the protective effect of tranexamic 
acid was also mediated by inhibition of plasmin(ogen) activity.  There are two plausible 
mechanisms for the effect of tranexamic acid.  Firstly, tranexamic acid may inhibit the 
conversion of plasminogen to plasmin.  Plasminogen binds to fibrin and cell surface through 
lysine-binding sites located in kringle domain (Hajjar et al., 1986; Wu et al., 1990), which 
promotes the conversion of plasminogen by tissue-type plasminogen activator (Miles et al., 
2005; Plow et al., 1995).  Lysine analogs such as tranexamic acid reversibly bind to the 
kringle domain (Prentice, 1980), decreasing plasmin production (Ellis et al., 1991).  
Secondly, interference of association of plasmin(ogen) with cell surface may be responsible 
for the effect of tranexamic acid.  For example, G-protein-coupled receptors sensitive to 
pertussis toxin have been shown to function as a plasmin receptor in monocytes and 
endothelial cells (Chang et al., 1993; Syrovets et al., 1997).  Since the responses of these 
cells to plasmin were inhibited by tranexamic acid, actions of plasmin may be mediated not 
only by its protease activity but also by its binding to unidentified cell surface receptors 
through kringle domain (Chang et al., 1993; Syrovets et al., 1997).  Another report in this 
context has shown that α-enolase is expressed on the surface of neurons as a plasminogen 
receptor, and that binding of plasminogen to neurons is abolished by tranexamic acid 
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(Nakajima et al., 1994).  Possible involvement of protease activity and receptors of 
plasmin(nogen) in potentiation of thrombin neurotoxicity remains to be addressed. 
  Argatroban, a thrombin inhibitor, abolished cortical injury induced by a combination of 
thrombin and plasminogen, confirming that protease activity of thrombin was crucial for the 
combined neurotoxicity.  Moreover, inhibitors of ERK pathway, Src family tyrosine kinase, 
PKC and de novo protein synthesis prevented the combined neurotoxicity, whereas an 
inhibitor of p38 MAPK was without effect and an inhibitor of JNK exacerbated the injury.  
These pharmacological profiles totally mimic those of neurotoxicity of a higher concentration 
of thrombin (Fujimoto et al., 2006).  Thus, plasminogen may potentiate thrombin 
neurotoxicity by allowing low concentrations of thrombin to effectively recruit neurotoxic 
signaling mechanisms.  Surprisingly, persistent ERK phosphorylation in response to 
plasminogen was exclusively observed in astrocytes, although thrombin-induced ERK 
phosphorylation has been observed mainly in neurons (Fujimoto et al., 2006).  These results 
imply that some cell-to-cell interactions between astrocytes and neurons should be involved in 
potentiation of thrombin neurotoxicity by plasminogen.  ERK phosphorylation in astrocytes 
is known to trigger astrogliosis accompanied by proliferation and expression of 
cyclooxygenase (Brambilla et al., 2002; Mandell and VandenBerg, 1999), and astrogliosis is 
observed in many neurodegenerative conditions (Pekny and Nilsson, 2005).  Because 
reactive astrocytes release various inflammation-related molecules including cytokines (Hu et 
al., 1997; Suzumura et al., 2006), activation of astrocytes by plasminogen may lead to 
enhanced release of cytokines that make neurons vulnerable to thrombin.  This possibility 
should also be addressed in future investigations.  Finally, we cannot formally exclude the 
possibility that the protease activity of thrombin itself is somehow enhanced by 
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plasminogen/plasmin. 
  Potentiation of thrombin neurotoxicity by plasminogen in the cerebral cortex was also 
observed in a rat brain microinjection model, suggesting that the same cellular mechanisms of 
synergistic cytotoxicity of thrombin and plasminogen as those in vitro also operate in vivo.  
Moreover, involvement of plasminogen in hemorrhagic brain injury was ascertained by the 
protective effect of aprotinin against cortical injury in a collagenase-induced hemorrhage 
model.  As demonstrated in our recent study of intrastriatal hemorrhage (Ohnishi et al., 
2007), the hematoma region contained remaining viable neurons as revealed by NeuN 
immunoreactivity, and we observed a significant protective effect of aprotinin as the increase 
in the number of NeuN-positive cells.  Aprotinin and tranexamic acid in the present study 
did not reduce the hematoma size in the cortex.  Although these drugs have been clinically 
used to prevent blood loss (Engles, 2005; Mahdy and Webster, 2004), prior administration of 
high doses of aprotinin and tranexamic acid is required to prevent uncontrolled plasma 
extravasation in vivo (O'Brien et al., 2000).  Therefore, relatively weak neuroprotective 
effects of aprotinin and tranexamic acid systemically administered in the present study might 
be attributable to insufficient inhibition of plasmin activity by these drugs.  Recently, 
molecules that promote blood coagulation and prevent hematoma growth, such as 
recombinant factor VII, attract considerable interests as a therapeutic strategy against ICH 
(Mayer and Rincon, 2005; Mayer et al., 2005).  Because inhibition of plasmin is expected to 
reduce hemorrhage and also to prevent neuronal injury mediated by protease activity, 
regulation of plasminogen/plasmin system could be an attractive therapeutic intervention. 
  In conclusion, we demonstrated here that plasminogen potentiated thrombin neurotoxicity 
in the cerebral cortex both in vitro and in vivo.  These effects of plasminogen appeared to be 
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mediated by plasmin protease activity and ERK phosphorylation in astrocytes.  Recently, 
exacerbation of thrombin-induced neuronal death by a combination with matrix 
metalloprotease-9 has been reported (Xue et al., 2006).  Elucidation of interactions of 
various protease systems with thrombin-mediated cytotoxic pathways may lead to discovery 
of novel therapeutic strategies for hemorrhagic brain injury 
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Figure legends 
Fig. 1.  Injury induced by thrombin and plasminogen in cortico-striatal slice cultures.  
(A-D) Representative images of PI fluorescence of whole slice cultures treated with vehicle 
(A), 30 U/ml thrombin alone (B), 30 U/ml thrombin plus 3 U/ml plasminogen (C) and 3 U/ml 
plasminogen alone (D) for 72 h.  Broken lines in each image indicate the striatal (left) and 
the cortical (right) regions, respectively.  Scale bars, 1 mm.  (E) A confocal image of the 
cortical region of a slice culture treated with thrombin (30 U/ml) and plasminogen (3 U/ml) 
for 72 h and immunostained for NeuN.  PI fluorescence (red) was colocalized with NeuN 
immunoreactivity (green) as indicated by arrowheads.  Scale bar, 20 μm.  (F-H) The 
cortical injury determined by the intensity of PI fluorescence at the center of the cortical 
region of slice cultures treated with increasing concentration of plasminogen (Plg) alone (F), 
combination of thrombin and plasminogen (G) and combination of NMDA and plasminogen 
(H) for 72 h.  For combination with NMDA, plasminogen was applied from 24 h before and 
concomitantly with NMDA exposure.  *** P < 0.001 vs. thrombin alone.  (I) The striatal 
shrinkage induced by thrombin and plasminogen at 72 h.  PC indicates slice cultures treated 
with 100 U/ml thrombin as a positive control. 
 
Fig. 2.  Involvement of plasmin activity in cortical injury induced by combination of 
thrombin and plasminogen.  (A, B) Time-dependent cleavage of S2251 reagent by 
serum-free medium with or without plasminogen (Plg, 3 U/ml) and plasmin (Pln, 0.1 U/ml) 
(A), and by supernatants of slice cultures treated with vehicle and plasminogen (Plg, 3 U/ml) 
(B).  The amount of cleaved product of S2251 was determined by absorbance at 450 nm.  
(C-F) Effects of aprotinin (AP, 20 μg/ml, C, E) and tranexamic acid (TX, 3 mM, D, F) on 
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cortical injury induced by a combination of 30 U/ml thrombin and 3 U/ml plasminogen (C, D) 
or by 100 U/ml thrombin (E, F).  ** P < 0.01, *** P < 0.001 vs. thrombin alone, ## P < 0.01, 
### P < 0.001. 
 
Fig. 3.  Effects of PD98059 (100 μM, A), PP2 (100 μM, B), bisindolylmaleimide (BIM, 3 
μM, C), cycloheximide (CHX, 1 μg/ml, D), argatroban (ARG, 300 μM, E), SB203580 (100 
μM, F), clodronate (CLO, 100 μg/ml, G) and SP600125 (100 μM, H) on cortical injury 
induced by a combination of thrombin and plasminogen.  Clodronate was applied from 72 h 
before and during thrombin/plasminogen application. Other agents were comcomitantly 
applied with thrombin/plasminogen.  * P < 0.05, ** P < 0.01, *** P < 0.001 vs. thrombin 
alone, ## P < 0.01, ### P < 0.001. 
 
Fig. 4.  Phosphorylation of ERK induced by thrombin and plasminogen.  (A) Slice cultures 
treated with vehicle (V), 30 U/ml thrombin alone (T), 30 U/ml thrombin plus 3 U/ml 
plasminogen (T+P) or 3 U/ml plasminogen alone (P) were harvested at 3 h and 24 h and 
homogenized.  Samples were subjected to Western blot analysis with specific antibodies 
against phosphorylated ERK and total ERK.  (B, C) Confocal microscopic images of 
immunofluorescence of phosphorylated ERK (green) and cell type specific markers (red) after 
3 h of plasminogen (3 U/ml) exposure in the cortical region of slice cultures.  
Immunofluorescence of phosphorylated ERK was colocalized with GFAP (B) but not with 
NeuN (C).  Arrowheads indicate colocalization.  Scale bars, 20 μm. 
 
Fig. 5.  Plasminogen potentiates thrombin-induced cortical neuron loss in vivo.  (A, B) 
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Representative images of NeuN-immunostained coronal brain sections prepared from rats that 
received intracortical injection of thrombin (1 U) alone (A) and thrombin (1 U) with 
plasminogen (0.3 U) at 72 h (B).  Scale bars, 1 mm.  (C) Effect of plasminogen (0.3 U) on 
thrombin (1 U)-induced cortical injury.  The extent of cortical injury was assessed by the 
injured area defined as the region with scarce NeuN immunoreactivity around the injection 
site.  Statistical difference was evaluated by Mann-Whitney test (n=10 for each group). 
 
Fig. 6.  Involvement of plasmin in hemorrhage-induced cortical injury.  (A-H) 
Representative images of NeuN-immunostained coronal brain sections prepared from rats that 
received intracortical collagenase (0.1 U) injection followed by intraperitoneal administration 
of saline (2 ml/kg/day, A, B, E, F), aprotinin (2 mg/kg/day, C, G) and tranexamic acid (300 
mg/kg/day, D, H) with low (A-D) and high (E-H) magnification.  Panels A and E show the 
images of the contralateral side of the brain from a saline-administered rat as a control.  
Brain sections were obtained 72 h after collagenase injection.  Scale bars, 1 mm (A-D) and 
50 μm (E-H), respectively.  (I) Effects of aprotinin (AP, 2 mg/kg/day) and tranexamic acid 
(TX, 300 mg/kg/day) on the decrease of NeuN-positive cells at the center of hematoma.  * P 
< 0.05 vs. saline, ### P < 0.001 vs. contralateral (Contra) cortex of saline-administered rats 
(n=7 – 10 for each group). 
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